Gelareh Homayounfar, MD
Dermatology · Mountain View
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 14
- 2 carriers
- Office
- 1
Offices
1 location · Sutter Bay Medical Foundation · 3,783 clinicians in this group
Plans that list them
14 plans · 2 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Homayounfar’s office at (650) 691-6174 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
14 of 14 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Sutter Advantage +More (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
California Medical Board record
Licence A153765 · Current
Licensed to practise in California · since 2018 · expires 2027-12-31 · Harvard Medical School.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Original Medicare doctor bills
$134,477
Medicare paid this office $134,477 for 403 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Short return visit (20+ min) | 251 | $30,202 | $75 |
| Return visit (30+ min) | 165 | $27,399 | $110 |
| Biopsy of related skin growth, first growth | 182 | $22,472 | $90 |
| Destruction of skin growth, 1-14 growths | 85 | $13,247 | $111 |
| Destruction of precancer skin growth, 1 growth | 154 | $11,366 | $46 |
See all 12 services
| Short return visit (20+ min) | 251 | $30,202 | $75 |
| Return visit (30+ min) | 165 | $27,399 | $110 |
| Biopsy of related skin growth, first growth | 182 | $22,472 | $90 |
| Destruction of skin growth, 1-14 growths | 85 | $13,247 | $111 |
| Destruction of precancer skin growth, 1 growth | 154 | $11,366 | $46 |
| Biopsy of related skin growth, each additional growth | 63 | $5,150 | $52 |
| Punch biopsy, first skin growth | 36 | $5,011 | $128 |
| Destruction of precancer skin growth, 2-14 growths | 113 | $4,809 | $7 |
| New patient visit (30+ min) | 36 | $3,409 | $95 |
| Application of ultraviolet light to skin | 17 | $3,106 | $28 |
| New patient visit (45+ min) | 20 | $2,771 | $139 |
| Short return visit | 12 | $617 | $51 |
Procedures Medicare counted
| Removal of skin lesions | 585 | More than 88% of doctors who do this |
| Removal or shaving of skin growth | 23 | More than 72% of doctors who do this |
| Skin biopsy | 313 | More than 91% of doctors who do this |
Who their Medicare patients are
403 Original Medicare patients in 2024. Average age 75 · Under 65 3% · 85 and older 12% · Women 55% · Also on Medicaid 6% · Health risk score 0.87. At or below the middle of the specialty; the typical dermatology clinician is at 1.01.
Conditions among them: High blood pressure 57% · Chronic kidney disease 18% · Cancer 18% · Diabetes 17% · Coronary heart disease 16% · Depression 14% · Atrial fibrillation 9% · Heart failure 7% · Dementia 5% · COPD 4% · Stroke 4%.
The office billed $490,169, Medicare allowed $186,471 and paid $134,477; for 2,331 services of 27 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 403 | 2,331 | 75 | 0.87 | $490,169 | $134,477 |
| 2023 | 393 | 1,986 | 75 | 0.88 | $404,516 | $116,220 |
| 2022 | 371 | 1,460 | 75 | 0.82 | $287,746 | $83,068 |
| 2021 | 200 | 607 | 75 | 0.87 | $132,362 | $37,982 |
| 2020 | 289 | 1,062 | 75 | 1.08 | $195,860 | $52,023 |
| 2019 | 179 | 530 | 74 | 1.05 | $108,055 | $31,232 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 12 services
| Short return visit (20+ min) | 226 | $23,215 | $76 |
| Return visit (30+ min) | 141 | $22,893 | $112 |
| Biopsy of related skin growth, first growth | 168 | $20,784 | $99 |
| Destruction of precancer skin growth, 1 growth | 148 | $10,255 | $50 |
| Destruction of skin growth, 1-14 growths | 45 | $6,014 | $116 |
| Destruction of precancer skin growth, 2-14 growths | 114 | $4,439 | $7 |
| Biopsy of related skin growth, each additional growth | 66 | $4,407 | $52 |
| New patient visit (30+ min) | 40 | $4,165 | $104 |
| Punch biopsy, first skin growth | 29 | $3,922 | $131 |
| New patient visit (45+ min) | 24 | $3,809 | $159 |
| Application of ultraviolet light to skin | 20 | $3,518 | $28 |
| Short return visit | 14 | $850 | $57 |
2022: 12 services
| Short return visit (20+ min) | 171 | $15,683 | $73 |
| Biopsy of related skin growth, first growth | 124 | $15,505 | $103 |
| Return visit (30+ min) | 107 | $14,708 | $109 |
| Destruction of precancer skin growth, 1 growth | 117 | $6,870 | $48 |
| Destruction of skin growth, 1-14 growths | 27 | $3,717 | $113 |
| New patient visit (45+ min) | 26 | $3,688 | $142 |
| New patient visit (30+ min) | 39 | $3,364 | $86 |
| Destruction of precancer skin growth, 2-14 growths | 88 | $3,138 | $7 |
| Biopsy of related skin growth, each additional growth | 40 | $3,026 | $54 |
| Application of ultraviolet light to skin | 21 | $2,737 | $27 |
| New patient visit (15+ min) | 15 | $864 | $58 |
| Short return visit | 19 | $816 | $43 |
2021: 8 services
| Return visit (30+ min) | 67 | $8,280 | $106 |
| Short return visit (20+ min) | 77 | $6,423 | $75 |
| Biopsy of related skin growth, first growth | 43 | $4,916 | $98 |
| Destruction of precancer skin growth, 1 growth | 52 | $2,890 | $49 |
| New patient visit (30+ min) | 21 | $1,853 | $88 |
| New patient visit (45+ min) | 13 | $1,754 | $135 |
| Biopsy of related skin growth, each additional growth | 17 | $1,213 | $51 |
| Destruction of precancer skin growth, 2-14 growths | 37 | $1,064 | $7 |
2020: 10 services
| Biopsy of related skin growth, first growth | 94 | $9,733 | $88 |
| Short return visit (20+ min) | 133 | $9,670 | $59 |
| Destruction of precancer skin growth, 1 growth | 87 | $5,631 | $47 |
| Return visit (30+ min) | 56 | $5,100 | $88 |
| New patient visit (15+ min) | 67 | $3,674 | $55 |
| Short return visit | 75 | $3,137 | $36 |
| Biopsy of related skin growth, each additional growth | 28 | $2,139 | $52 |
| Destruction of skin growth, 1-14 growths | 19 | $2,082 | $99 |
| Destruction of precancer skin growth, 2-14 growths | 58 | $1,647 | $6 |
| Punch biopsy, first skin growth | 11 | $1,442 | $131 |
2019: 9 services
| Short return visit (20+ min) | 79 | $5,932 | $71 |
| Biopsy of related skin growth, first growth | 54 | $5,753 | $94 |
| New patient visit (15+ min) | 48 | $3,186 | $66 |
| Destruction of skin growth, 1-14 growths | 23 | $2,773 | $107 |
| Destruction of precancer skin growth, 1 growth | 45 | $2,621 | $51 |
| New patient visit (30+ min) | 22 | $2,087 | $95 |
| Short return visit | 22 | $1,183 | $44 |
| Biopsy of related skin growth, each additional growth | 12 | $749 | $53 |
| Destruction of precancer skin growth, 2-14 growths | 32 | $748 | $6 |
Drugs they prescribed that Part D paid
$618,406
Pharmacies billed $618,406 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 717) in 2024. At or below the middle of the specialty; the typical dermatology clinician is at 0%.
642 generic and 75 brand-name prescriptions · $618,406 in drug cost · 38 antibiotic prescriptions to 22 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Stelara | 15 | $299,386 | $19,959 |
| Humira(Cf) | 12 | $159,697 | $13,308 |
| Humira | 13 | $86,610 | $6,662 |
| Tacrolimus | 24 | $5,182 | $216 |
| Betamethasone Dipropionate | 32 | $2,437 | $76 |
See all 20 drugs
| Stelara | 15 | $299,386 | $19,959 |
| Humira(Cf) | 12 | $159,697 | $13,308 |
| Humira | 13 | $86,610 | $6,662 |
| Tacrolimus | 24 | $5,182 | $216 |
| Betamethasone Dipropionate | 32 | $2,437 | $76 |
| Clindamycin Phosphate | 25 | $2,318 | $93 |
| Ketoconazole | 141 | $2,108 | $15 |
| Calcipotriene | 20 | $2,086 | $104 |
| Fluocinonide | 50 | $1,645 | $33 |
| Clobetasol Propionate | 28 | $1,190 | $42 |
| Fluorouracil | 22 | $1,133 | $51 |
| Tretinoin | 11 | $945 | $86 |
| Ciclopirox | 34 | $888 | $26 |
| Metronidazole | 17 | $820 | $48 |
| Betamethasone Diprop Augmented | 24 | $615 | $26 |
| Triamcinolone Acetonide | 50 | $532 | $11 |
| Doxycycline Hyclate | 21 | $491 | $23 |
| Hydrocortisone | 47 | $353 | $8 |
| Doxycycline Monohydrate | 16 | $228 | $14 |
| Mupirocin | 30 | $195 | $7 |
Year by year
| 2024 | 717 | 237 | 0% (0) | 10% | $618,406 |
| 2023 | 661 | 226 | 0% (0) | 9% | $423,110 |
| 2022 | 507 | 200 | 0% (0) | 9% | $214,241 |
| 2021 | 293 | 119 | 0% (0) | 9% | $162,211 |
| 2020 | 409 | 135 | 0% (0) | 8% | $120,583 |
| 2019 | 111 | 55 | 0% (0) | None | $3,842 |
| 2018 | 95 | 31 | 0% (0) | None | $7,027 |
| 2017 | 147 | 44 | 0% (0) | 17% | $24,976 |
| 2016 | 42 | 17 | 0% (0) | None | $4,902 |
| 2015 | 39 | 14 | None | None | $3,243 |
| 2014 | 39 | 14 | None | None | $2,035 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 17 drugs
| Stelara | 13 | $268,148 | $20,627 |
| Ketoconazole | 132 | $3,776 | $29 |
| Tacrolimus | 17 | $3,502 | $206 |
| Betamethasone Dipropionate | 29 | $2,780 | $96 |
| Clindamycin Phosphate | 27 | $2,668 | $99 |
| Fluocinonide | 46 | $2,599 | $56 |
| Calcipotriene | 21 | $2,381 | $113 |
| Clobetasol Propionate | 31 | $2,017 | $65 |
| Fluorouracil | 27 | $1,860 | $69 |
| Ciclopirox | 23 | $1,086 | $47 |
| Betamethasone Diprop Augmented | 24 | $910 | $38 |
| Doxycycline Hyclate | 22 | $665 | $30 |
| Triamcinolone Acetonide | 48 | $538 | $11 |
| Hydrocortisone | 58 | $395 | $7 |
| Mupirocin | 33 | $352 | $11 |
| Mometasone Furoate | 13 | $225 | $17 |
| Finasteride | 11 | $79 | $7 |
2022: 16 drugs
| Calcipotriene | 22 | $3,198 | $145 |
| Fluorouracil | 25 | $2,798 | $112 |
| Tacrolimus | 16 | $2,776 | $173 |
| Ketoconazole | 102 | $2,675 | $26 |
| Fluocinonide | 51 | $2,537 | $50 |
| Betamethasone Dipropionate | 18 | $1,378 | $77 |
| Clobetasol Propionate | 15 | $1,119 | $75 |
| Betamethasone Diprop Augmented | 13 | $1,097 | $84 |
| Doxycycline Hyclate | 19 | $818 | $43 |
| Metronidazole | 13 | $781 | $60 |
| Ciclopirox | 11 | $665 | $60 |
| Triamcinolone Acetonide | 49 | $501 | $10 |
| Clindamycin Phosphate | 12 | $455 | $38 |
| Mometasone Furoate | 24 | $319 | $13 |
| Mupirocin | 21 | $278 | $13 |
| Hydrocortisone | 34 | $265 | $8 |
2021: 9 drugs
| Ketoconazole | 56 | $1,339 | $24 |
| Fluocinonide | 29 | $1,269 | $44 |
| Clobetasol Propionate | 15 | $685 | $46 |
| Valacyclovir | 11 | $675 | $61 |
| Triamcinolone Acetonide | 46 | $657 | $14 |
| Ciclopirox | 12 | $342 | $29 |
| Doxycycline Hyclate | 15 | $321 | $21 |
| Mupirocin | 21 | $192 | $9 |
| Hydrocortisone | 12 | $83 | $7 |
2020: 10 drugs
| Ketoconazole | 100 | $2,561 | $26 |
| Fluocinonide | 43 | $2,355 | $55 |
| Calcipotriene | 11 | $1,261 | $115 |
| Clobetasol Propionate | 11 | $744 | $68 |
| Clindamycin Phosphate | 12 | $700 | $58 |
| Triamcinolone Acetonide | 50 | $606 | $12 |
| Ciclopirox | 15 | $495 | $33 |
| Valacyclovir | 11 | $399 | $36 |
| Mupirocin | 42 | $386 | $9 |
| Hydrocortisone | 41 | $240 | $6 |
2019: 3 drugs
| Ketoconazole | 31 | $795 | $26 |
| Fluocinonide | 13 | $757 | $58 |
| Triamcinolone Acetonide | 18 | $135 | $7 |
2018: 2 drugs
| Ketoconazole | 25 | $1,096 | $44 |
| Triamcinolone Acetonide | 19 | $289 | $15 |
2017: 4 drugs
| Ketoconazole | 35 | $1,572 | $45 |
| Fluocinolone Acetonide | 13 | $1,524 | $117 |
| Clindamycin Phosphate | 11 | $1,010 | $92 |
| Triamcinolone Acetonide | 24 | $273 | $11 |
Money from drug and device companies
$900 in 2025
| 2025 | 14 | 33 | None | $900 |
| 2024 | 11 | 29 | None | $862 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Genzyme | Dupixent | $130 | 3 payments
|
| Janssen Biotech | Tremfya | $127 | 5 payments
|
| Galderma Laboratories L.P. | Nemluvio | $86 | 4 payments
|
| Sanofi-Aventis U.S. | Dupixent | $85 | 1 payment
|
| Incyte | Opzelura | $84 | 4 payments
|
| Novartis Pharmaceuticals | Cosentyx | $66 | 3 payments
|
See all 33 published payments
| Incyte | Meals · 2025-12-02 | Opzelura | $17 |
| Pfizer | Meals · 2025-12-02 | Cibinqo | $30 |
| Incyte | Meals · 2025-11-04 | Opzelura | $26 |
| Galderma Laboratories L.P. | Meals · 2025-10-27 | Nemluvio | $26 |
| Genzyme | Meals · 2025-10-20 | Dupixent | $47 |
| Lilly USA | Meals · 2025-10-13 | Taltz | $32 |
| Novartis Pharmaceuticals | Meals · 2025-10-09 | Rhapsido | $21 |
| Arcutis Biotherapeutics | Meals · 2025-09-16 | Zoryve | $19 |
| Janssen Biotech | Meals · 2025-09-15 | Tremfya | $14 |
| Galderma Laboratories L.P. | Meals · 2025-08-11 | None | $18 |
| Janssen Biotech | Meals · 2025-08-04 | Tremfya | $23 |
| Galderma Laboratories L.P. | Meals · 2025-08-04 | Nemluvio | $23 |
| Organon | Meals · 2025-07-22 | Vtama | $26 |
| Revance Therapeutics | Meals · 2025-07-22 | Daxi | $30 |
| Arcutis Biotherapeutics | Meals · 2025-07-22 | Zoryve | $16 |
| Janssen Biotech | Meals · 2025-07-14 | Tremfya | $34 |
| Abbvie | Meals · 2025-07-01 | Skyrizi | $17 |
| Incyte | Meals · 2025-06-04 | Opzelura | $16 |
| Genzyme | Meals · 2025-05-20 | Dupixent | $41 |
| Galderma Laboratories L.P. | Meals · 2025-05-19 | Nemluvio | $19 |
| Novartis Pharmaceuticals | Meals · 2025-05-08 | Cosentyx | $18 |
| Janssen Biotech | Meals · 2025-05-06 | Tremfya | $25 |
| Lilly USA | Meals · 2025-04-28 | Taltz | $25 |
| Arcutis Biotherapeutics | Meals · 2025-04-14 | Zoryve | $18 |
| Organon | Meals · 2025-03-17 | Hadlima | $34 |
| Sanofi-Aventis U.S. | Education · 2025-03-04 | Dupixent | $85 |
| Almirall | Meals · 2025-02-11 | Klisyri | $19 |
| Incyte | Meals · 2025-02-05 | Opzelura | $24 |
| Genzyme | Meals · 2025-02-03 | Dupixent | $42 |
| Novartis Pharmaceuticals | Meals · 2025-01-28 | Cosentyx | $27 |
| Abbvie | Meals · 2025-01-21 | Skyrizi | $35 |
| Janssen Biotech | Meals · 2025-01-17 | Tremfya | $30 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-01-13 | Sotyktu | $22 |
See earlier years (2024)
2024: $862
| E.R. Squibb & Sons L.L.C. | Sotyktu | $157 | 6 payments
|
| Janssen Biotech | Tremfya | $138 | 2 payments
|
| Genzyme | Dupixent | $115 | 3 payments
|
| Incyte | Opzelura | $105 | 4 payments
|
| Arcutis Biotherapeutics | Zoryve | $88 | 4 payments
|
| Regeneron Healthcare Solutions | Dupixent | $81 | 3 payments
|
| Lilly USA | Taltz | $58 | 2 payments
|
| Novartis Pharmaceuticals | Cosentyx | $50 | 2 payments
|
| Galderma Laboratories L.P. | None | $25 | 1 payment
|
| Pfizer | Litfulo | $25 | 1 payment
|
| Almirall | Klisyri | $20 | 1 payment
|
Professional record
- NPI
- 1598178626
- Licence
- CA A153765California A153765: Current · expires 2027-12-31
- Trained
- Harvard Medical School, 2014
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207N00000X (207N00000X)
- Mailing address
- 325 Distel Cir, Los Altos, CA, 94022
- NPI first listed
- 2014-06-05
- NPI last updated
- 2019-07-22
This is when the NPI record was last certified, not a medical board exam.